Olympus Deep Learning AI-Based Pathology Diagnostic Tool Advances to the Multicenter Testing PhaseJointly developed computer-assisted diagnostic tool will be refined and tested using data from multiple hospitals in Japan
November 16, 2020
Beginning in 2017, Olympus’ proprietary deep-learning technology has been used in a joint research program to create an AI-based pathology diagnostic tool with the potential to streamline pathologists’ workloads. The program has two phases; phase 1 testing demonstrated the tool’s effectiveness at identifying adenocarcinoma (ADC) tissue in images. Phase 2 testing at six hospitals in Japan*1 is now beginning with the aim of further refining the tool in preparation for commercialization. This AI testing phase is expected to last for three years.
*1 National Hospital Organization Kure Medical Center and Chugoku Cancer Center, National Hospital Organization Osaka National Hospital, National Hospital Organization Shikoku Cancer Center, National Hospital Organization Nagasaki Medical Center, Hiroshima Memorial Hospital, Kure Medical Association Hospital
Press releases are company announcements that are directed at the news media.
Information posted on this site is current and accurate only at the time of their original publication date, and may now be outdated or inaccurate.